Literature DB >> 22865937

Synthesis of CJ-15,208, a novel κ-opioid receptor antagonist.

Nicolette C Ross1, Santosh S Kulkarni, Jay P McLaughlin, Jane V Aldrich.   

Abstract

The tryptophan isomers of the cyclic tetrapeptide CJ-15,208, reported to be a kappa opioid receptor (KOR) antagonist [Saito, T.; Hirai, H.; Kim, Y. J.; Kojima, Y.; Matsunaga, Y.; Nishida, H.; Sakakibara, T.; Suga, O.; Sujaku, T.; Kojima, N. J. Antibiot. (Tokyo)2002, 55, 847-854.], were synthesized to determine the tryptophan stereochemistry in the natural product. A strategy was developed to select linear precursor peptides that favor cyclization using molecular modeling, and optimized cyclization conditions are reported. The optical rotation of the l-Trp isomer is consistent with that of the natural product. Unexpectedly both isomers exhibit similar nanomolar affinity for KOR.

Entities:  

Year:  2010        PMID: 22865937      PMCID: PMC3411353          DOI: 10.1016/j.tetlet.2010.07.086

Source DB:  PubMed          Journal:  Tetrahedron Lett        ISSN: 0040-4039            Impact factor:   2.415


  16 in total

1.  Study on the cyclization tendency of backbone cyclic tetrapeptides.

Authors:  D Besser; R Olender; R Rosenfeld; O Arad; S Reissmann
Journal:  J Pept Res       Date:  2000-12

2.  FR235222, a fungal metabolite, is a novel immunosuppressant that inhibits mammalian histone deacetylase III. Structure determination.

Authors:  Hiroaki Mori; Yasuharu Urano; Takayoshi Kinoshita; Seiji Yoshimura; Shigehiro Takase; Motohiro Hino
Journal:  J Antibiot (Tokyo)       Date:  2003-02       Impact factor: 2.649

Review 3.  The cyclization of peptides and depsipeptides.

Authors:  John S Davies
Journal:  J Pept Sci       Date:  2003-08       Impact factor: 1.905

4.  Isolation and structural elucidation of new cyclotetrapeptides, trapoxins A and B, having detransformation activities as antitumor agents.

Authors:  H Itazaki; K Nagashima; K Sugita; H Yoshida; Y Kawamura; Y Yasuda; K Matsumoto; K Ishii; N Uotani; H Nakai
Journal:  J Antibiot (Tokyo)       Date:  1990-12       Impact factor: 2.649

Review 5.  Kappa opioid antagonists: past successes and future prospects.

Authors:  Matthew D Metcalf; Andrew Coop
Journal:  AAPS J       Date:  2005-10-27       Impact factor: 4.009

6.  [Isolation and structural clarification of chlamydocin].

Authors:  A Closse; R Huguenin
Journal:  Helv Chim Acta       Date:  1974-04-27       Impact factor: 2.164

7.  All-L-Leu-Pro-Leu-Pro: a challenging cyclization.

Authors:  M E Haddadi; F Cavelier; E Vives; A Azmani; J Verducci; J Martinez
Journal:  J Pept Sci       Date:  2000-11       Impact factor: 1.905

8.  Cyclotetrapeptides and cyclopentapeptides: occurrence and synthesis.

Authors:  U Schmidt; J Langner
Journal:  J Pept Res       Date:  1997-01

Review 9.  Peptide kappa opioid receptor ligands: potential for drug development.

Authors:  Jane V Aldrich; Jay P McLaughlin
Journal:  AAPS J       Date:  2009-05-09       Impact factor: 4.009

10.  CJ-15,208, a novel kappa opioid receptor antagonist from a fungus, Ctenomyces serratus ATCC15502.

Authors:  Toshiyuki Saito; Hideo Hirai; Yoon-Jeong Kim; Yasuhiro Kojima; Yasue Matsunaga; Hiroyuki Nishida; Tatsuo Sakakibara; Osamu Suga; Tetsujo Sujaku; Nakao Kojima
Journal:  J Antibiot (Tokyo)       Date:  2002-10       Impact factor: 2.649

View more
  14 in total

1.  Novel opioid cyclic tetrapeptides: Trp isomers of CJ-15,208 exhibit distinct opioid receptor agonism and short-acting κ opioid receptor antagonism.

Authors:  Nicolette C Ross; Kate J Reilley; Thomas F Murray; Jane V Aldrich; Jay P McLaughlin
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

2.  'Carba'-carfentanil (trans isomer): a μ opioid receptor (MOR) partial agonist with a distinct binding mode.

Authors:  Grazyna Weltrowska; Carole Lemieux; Nga N Chung; Jason J Guo; Brian C Wilkes; Peter W Schiller
Journal:  Bioorg Med Chem       Date:  2014-07-29       Impact factor: 3.641

3.  Synthesis of endolides A and B: naturally occurring N-methylated cyclic tetrapeptides.

Authors:  Emma K Davison; Alan J Cameron; Paul W R Harris; Margaret A Brimble
Journal:  Medchemcomm       Date:  2019-03-05       Impact factor: 3.597

4.  Macrocyclic peptides decrease c-Myc protein levels and reduce prostate cancer cell growth.

Authors:  Archana Mukhopadhyay; Laura E Hanold; Hamsa Thayele Purayil; Solomon A Gisemba; Sanjeewa N Senadheera; Jane V Aldrich
Journal:  Cancer Biol Ther       Date:  2017-07-10       Impact factor: 4.742

5.  Unexpected opioid activity profiles of analogues of the novel peptide kappa opioid receptor ligand CJ-15,208.

Authors:  Jane V Aldrich; Santosh S Kulkarni; Sanjeewa N Senadheera; Nicolette C Ross; Kate J Reilley; Shainnel O Eans; Michelle L Ganno; Thomas F Murray; Jay P McLaughlin
Journal:  ChemMedChem       Date:  2011-07-14       Impact factor: 3.466

6.  Alanine analogues of [D-Trp]CJ-15,208: novel opioid activity profiles and prevention of drug- and stress-induced reinstatement of cocaine-seeking behaviour.

Authors:  J V Aldrich; S N Senadheera; N C Ross; K A Reilley; M L Ganno; S E Eans; T F Murray; J P McLaughlin
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

7.  The macrocyclic peptide natural product CJ-15,208 is orally active and prevents reinstatement of extinguished cocaine-seeking behavior.

Authors:  Jane V Aldrich; Sanjeewa N Senadheera; Nicolette C Ross; Michelle L Ganno; Shainnel O Eans; Jay P McLaughlin
Journal:  J Nat Prod       Date:  2013-01-17       Impact factor: 4.050

8.  The macrocyclic tetrapeptide [D-Trp]CJ-15,208 produces short-acting κ opioid receptor antagonism in the CNS after oral administration.

Authors:  Shainnel O Eans; Michelle L Ganno; Kate J Reilley; Kshitij A Patkar; Sanjeewa N Senadheera; Jane V Aldrich; Jay P McLaughlin
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

9.  Opioid Peptides: Potential for Drug Development.

Authors:  Jane V Aldrich; Jay P McLaughlin
Journal:  Drug Discov Today Technol       Date:  2012

Review 10.  Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects.

Authors:  Kelly F Paton; Diana V Atigari; Sophia Kaska; Thomas Prisinzano; Bronwyn M Kivell
Journal:  J Pharmacol Exp Ther       Date:  2020-09-10       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.